Chronic obstructive pulmonary disease: a concise review.
Globally, chronic obstructive pulmonary disease (COPD) is a major cause of significant morbidity and mortality, and is now the third leading cause of death in the United States. Over the past 15 years there has been a surge of bench and translational research regarding the genetics and pathogenesis of COPD, and several large-scale clinical trials have introduced new treatment paradigms for COPD. Current research also demonstrates that COPD is not just a lung disease and that there are several potential extrapulmonary manifestations and comorbidities that should be evaluated and treated when one identifies an individual as having COPD.
National Jewish Health, Pulmonary Division, Department of Medicine, Denver, CO 80206, USA. balkissoonr@NJHealth.org
Ron
R
Balkissoon
Steve
S
Lommatzsch
Brendan
B
Carolan
Barry
B
Make
D000465:Algorithms; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001993:Bronchodilator Agents / Q000008:administration & dosage; D015897:Comorbidity; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D016040:Lung Transplantation; D011013:Pneumonectomy; D017410:Practice Guidelines as Topic; D029424:Pulmonary Disease, Chronic Obstructive / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology / Q000534:rehabilitation; D012307:Risk Factors; D013147:Spirometry; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D001993:Bronchodilator Agents; D005938:Glucocorticoids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors